Investing In Medical Nanotechnologies

Investing in Medical Nanotechnologies Conference and Exhibition 2006 13th and 14th December, Royal Garden Hotel, London Day 1- 13th December 2006 08.30-09.30

Registration

Session1: The promise of Nanomedicine 09.30-09.35

Welcome Note Ottilia Saxl, CEO, The Institute of Nanotechnology

09.35-10.05

Keynote /Introductory Presentation Prof. Sir Michael Rawlins, Chairman, National Institute of Clinical Excellence, UK

10.10-10.40

Keynote Presentation 2 Dr. Paul Smit, Senior Vice President, Philips Medical Systems

10.45-11.15

Tea & Coffee

11.15-11.45

The Role of Nanotechnology in Healthcare- Keynote Presentation Dr. Leonard Fass, Director, Academic Relations, GE Healthcare

11.50-12.20

Keynote Presentation 4 Dr. Arne Hengerer, Director, Molecular MRI, Siemens Medical Solutions

12.20-13.30

Lunch

Session 2:

Small Company Presentations – Nanotechnology in Drug Delivery, Implants, Devices and Regenerative Medicine

13.30-13.40

Nanobiotechnology at the Interface Dr. Dale Athey, Managing Director, Orla Protein Technologies Ltd

13.45-13.55

Functional Nanocoatings for Surface Biotechnology Dr. Jas Pal Badyal, Surface Innovation Technologies

14.00-14.10

Future non-biofouling materials by nanoscale surface modification Dr. Tessa ten Cate, TNO Science & Industry Title: Awaiting

14.15-14.25

Carbon coated nanomagnets for biomedical applications Dr. Rüdiger Klingeler, Institute for Solid State Research at IFW Dresden, Germany

14.30-14.40

Anti-cancer therapy using novel gene delivery technology Dr. Andreas Schatzlein, Founder and CSO Nanomerics

14.45-14.55

Nanomedicine and infectious diseases: the use of nanoviricides™ in the treatment of acute and chronic viral illnesses Dr. Eugene Seymour, Chief Executive Officer, Nanoviricides, Inc, USA

15.00-15.30

Tea/Coffee

15.30-15.40

Nanoparticle mediated cell killing gives unique safety for cell based therapies. Dr.Martin Roland Jensen, Nannovation Biotech

15.45-15.55

Neuronal regeneration using Nanotope technology Dr. Chris Anzalone, Nanotope

Session 3: Medical Nanotechnology- Patents, Regulation, Risks, Safety and Society Chair: Dr. Kamal Hossain, Director, National Physical Laboratory 16.00-16.15

Nanotechnology and risk: Insurability challenges and requirements for success Dr. Thomas K Epprecht, Senior Risk Specialist, Swiss Reinsurance Company

16.15-16.30

Title: TBC Dr. Marisa Papaluca Amati, Deputy Head of Sector, European Medicines Agency (EMEA)

16.30-16.45

Title: TBC Mr. Hilton Lord, Partner, Marks and Clerk

16.45-17.00

Lead Aerosol Size Distribution and Occupational Health Dr. Robert Muir, Innospan

17.00-17.30

Panel Discussion

17.30- 19.00

Networking

19.00-22.30

Gala Dinner

Day 2- 14th December 2006 08.30-09.30

Registration

Session 4:

Converging Technologies for Healthcare Applications

09.15-09.20

Welcome note

Chair: Prof. Shervanthi Homer Vanniasinkam 09.20-09.45

Keynote Presentation Dr Philippe Cleuziat, Technological Marketing Director, Biomerieux

09.50-10.10

Bionanotechnology in Australia Dr. Bob Irving, Scientific and Commercial Director, Nanotechnology Victoria Pty Ltd, Australia

10.15-10.30

Title: TBC Prof. Shervanthi Homer Vanniasinkam

10.35-11.05

Tea & Coffee

Session: 5

Small Company Presentations – Nanotechnology in Diagnostics, Imaging

Chair: 11.05-11.15

Novel Piezoelectric film technology for diagnostic applications Dr. Neil Butler, CEO, Vivacta

11.15-11.25

Electronic Nose Technology for the early detection of TB Dr. Tim Gibson, R&D Director, Scensive Technologies Limited

11.30-11.40

New Diagnostic Tests Based On Nanoparticles Functionalised By the Hand-In-Glove Method Dr. Maryam Mehrabi, University of Liverpool

11.45-11.55

Nanoplex™ Biotags: A Transformational Optical Detection Platform for Clinical and Point-Of-Care Diagnostics Dr. Peter Corish, Applications Manager Biodiagnostics Oxonica Healthcare

12.00-12.10

Endomagnetics: Making Magnets Work for Healthcare Prof. Q A Pankhurst, Deputy Director, London Centre for Nanotechnology

12.15-12.25

Label-free screening of bio-molecular interactions Dr.Mathew Cooper, Founder and CSO, Akubio Ltd.

12.30-13.30

Lunch

Session 6:

Investing in Medical Nanotechnologies- Evaluation, Finances and Challenges

Moderator - Del Stark, CEO, European Nanotechnology Trade Alliance 13.30-13.50

Medical Nanotechnology: Business Models, Financing and Valuation- Keynote Presentation Dr. Ogan Gurel, CEO, Duravest inc

13.50-14.10

EIB financing of Research, Development and Innovation Projects- Keynote Presentation Dr. Kim Kreilgaard, Head of Division, European Investment Bank

14.10-14.25

Are you ready for investment? (TBC) Paula Knee, Quotec Ltd

14.30-14.45

Industry Reputation issues affecting nanotech companies Dr. John Browne, Strategic Advantage

14.45-15.00

The Role of Technology Roadmaps in Making Investment Decisions in Nanotechnology Dr. Malcolm Wilkinson, Managing Director, Technology for Industry Ltd

15.00-15.30

Discussions

15.30-16.00

Tea/Coffee

16.00

End of Conference